Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...
Armed robbery in Revesby3h
Genome Activation Key in Rare Disease Treatment
Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and complex class of genetic ...
E!4h
Why Celebs Love Salmon Sperm Facials & How You Can Get Results at Home, According to a Dermatologist
According to Dr. Kim, "It'll be the year of PDRN (polydeoxyribonucleotide) derived from salmon sperm. These DNA fragments have been shown to improve tissue elasticity, firmness, and have an ...
Vitamin E succinate shown to control tumor growth and enhance immunotherapy effects
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
Q1 EPS Forecast for CRISPR Therapeutics Decreased by Analyst
Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...